Massachusetts General Hospital Cancer Center- Site Number : 1092 — Boston, Massachusetts

Massachusetts General Hospital Cancer Center- Site Number : 1092 is a clinical research site located in Boston, Massachusetts, United States 02114-2603.

Crixeo Health Trust Score: 51/100 (POOR). This profile has not yet been claimed by the site owner.

Massachusetts General Hospital Cancer Center- Site Number : 1092 has participated in 1 clinical trials.

Therapeutic areas: Immune Thrombocytopenia.

Sponsors: Principia Biopharma, a Sanofi Company.

Sponsor Feasibility Report

Trust Score: 51/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Massachusetts General Hospital Cancer Center- Site Number : 1092?

Massachusetts General Hospital Cancer Center- Site Number : 1092 has a Crixeo Trust Score of 51/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Massachusetts General Hospital Cancer Center- Site Number : 1092 conducted?

Massachusetts General Hospital Cancer Center- Site Number : 1092 has 1 clinical trials on record. Their work covers Immune Thrombocytopenia.

Is Massachusetts General Hospital Cancer Center- Site Number : 1092 accredited by Crixeo Health?

Massachusetts General Hospital Cancer Center- Site Number : 1092 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Massachusetts General Hospital Cancer Center- Site Number : 1092?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.